Clinical trials: Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral Sclerosis, ALS
Open-label Study to Evaluate Safety, Tolerability and PK of BHV-0223 in ALS
Phase 1, open-label study of BHV-0223 in ALS.
- Conditions
- Amyotrophic Lateral Sclerosis, ALS, Lou Gehrig Disease, Lou Gehrig's Disease
- Trial name
- NCT03520517
- Testing
- BHV-0223
- Where
- 5 sites in United States
- Volunteers
- 22 people
- Sponsor
- Biohaven Pharmaceuticals, Inc.
Amyotrophic Lateral Sclerosis
Counterfactual Thinking in Amyotrophic Lateral Sclerosis
The properness of our past choices and action is usually judged according to what could have been if we had behaved differently.
- Trial name
- CFTSLA (NCT05768646)
- Testing
- Neuropsychological instruments
- Where
- Italy
- Volunteers
- 157 people, healthy volunteers welcome
- Sponsor
- Istituto Auxologico Italiano
Amyotrophic Lateral Sclerosis
Effects of ODM-109 on Respiratory Function in Patients With Amyotrophic Lateral Sclerosis
In the double-blind, cross-over part of the study, ODM-109 capsules and placebo capsules for ODM-109 will be administered for 2 weeks separated by a 19-23 days wash-out period.
- Trial name
- ALS (NCT02487407)
- Testing
- ODM-109
- Where
- 11 sites in Germany, Ireland and 2 more
- Volunteers
- 66 people
- Sponsor
- Orion Corporation, Orion Pharma
Amyotrophic Lateral Sclerosis
Cistanche Total Glycosides for Amyotrophic Lateral Sclerosis: A Randomized Control Trial (RCT) Study Assessing Clinical Response
This study will examine the effectiveness of Cistanche Total Glycosides(CTG) in treating patients with amyotrophic lateral sclerosis (ALS) - a fatal neurological degenerative disease that causes adult-onset, progressive motor…
- Trial name
- NCT00753571
- Testing
- Cistanche Total Glycosides
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Peking University
Amyotrophic Lateral Sclerosis
A Study to Evaluate the Safety, Tolerability and Efficacy of ILB in Patients With Amyotrophic Lateral Sclerosis
This is a Phase 2a single-centre, open single-arm study in patients with Amyotrophic Lateral Sclerosis (ALS) of intermediate progression rate. Eligible subjects will be administered weekly doses of ILB.
- Trial name
- NCT03613571
- Testing
- ILB
- Where
- Sweden
- Volunteers
- 13 people
- Sponsor
- TikoMed AB
Amyotrophic Lateral Sclerosis (ALS)
Mitochondrial Capacity Boost in ALS (MICABO-ALS) Trial
The purpose of this research is to investigate the validity of a previous clinical trial named EH301, which showed beneficial effects of anti-oxidant therapies in patients with amyotrophic lateral sclerosis (ALS).
- Trial name
- MICABO-ALS (NCT04244630)
- Testing
- Antioxidants
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Dallas VA Medical Center
Amyotrophic Lateral Sclerosis
Needs of ALS Patients With C9orf72 Mutation and Their Caregivers
Individuals with Amyotrophic Lateral Sclerosis (ALS) carrying the C9orf72 HRE mutation (C9Pos) often exhibit different phenotypic traits compared to other patients (C9Neg), presenting a more aggressive form of the disease, with…
- Trial name
- C9survALS (NCT07302321)
- Testing
- Survey for ALS patients, Survey for Caregivers
- Where
- 3 sites in Italy
- Volunteers
- 208 people
- Sponsor
- Istituto Auxologico Italiano
Amyotrophic Lateral Sclerosis, Kennedy Disease
Cell Signaling, Reinnervation and Metabolism in Kennedy Disease and Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic lateral sclerosis (ALS), is a rapidly progressive neurodegenerative disorder, usually leading to death from respiratory failure in 3-5 years.
- Trial name
- CERMALS (NCT05107349)
- Testing
- Muscle biopsy
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Amyotrophic Lateral Sclerosis
Rapamycin Treatment for ALS
In the last years research has pointed out potential mechanisms of pathogenesis in ALS including lack of degradation of abnormally accumulated proteins inside motor neurons, and an unbalanced function of the immune system leading…
- Trial name
- RAP-ALS (NCT03359538)
- Testing
- Rapamycin
- Where
- 7 sites in Italy
- Volunteers
- 63 people
- Sponsor
- Azienda Ospedaliero-Universitaria di Modena
Amyotrophic Lateral Sclerosis
Treatment Continuation Study for Patients With ALS/MND Who Completed Study CMD-2019-001
Provides up to six months treatment with CuATSM for subjects who have successfully completed study CMD-2019-001
- Trial name
- NCT04313166
- Testing
- Cu(II)ATSM
- Where
- Australia
- Volunteers
- 55 people
- Sponsor
- Collaborative Medicinal Development Pty Limited
Locked in Syndrome, ALS (Amyotrophic Lateral Sclerosis)
Evaluation of the Feasibility and Efficacy of a Chronic Brain-computer Interface for Speech Rehabilitation in Patients With Locked-in-syndrome (LIS)
Eighteen million people worldwide are affected by speech disorders. Locked-in syndrome (LIS) represents the most extreme form of communication disability resulting from motor impairment.
- Trial name
- SpeechBCI (NCT07698496)
- Testing
- Chronic speech BCI
- Where
- 4 sites in France
- Volunteers
- 3 people
- Sponsor
- University Hospital, Grenoble
Amyotrophic Lateral Sclerosis
Individual Patient Expanded Access IND of Autologous HBadMSCs for the Treatment of Amyotrophic Lateral Sclerosis
The drug for this submission is Hope Biosciences' autologous, adipose-derived culture-expanded mesenchymal stem cells (HB-adMSCs) for the treatment of a single patient with Amyotrophic Lateral Sclerosis (ALS).
- Trial name
- NCT04514952
- Testing
- HB-adMSCs
- Where
- United States
- Sponsor
- Hope Biosciences Research Foundation
Neurologic Disorders, Nervous System Diseases
Neurologic Stem Cell Treatment Study
This is a human clinical study involving the isolation of autologous bone marrow derived stem cells (BMSC) and transfer to the vascular system and inferior 1/3 of the nasal passages in order to determine if such a treatment will…
- Conditions
- Neurologic Disorders, Nervous System Diseases, Neurodegenerative Diseases, Neurological Disorders
- Trial name
- NEST (NCT02795052)
- Testing
- Intravenous and Intranasal BMSC
- Where
- 3 sites in United States, United Arab Emirates
- Volunteers
- 500 people
- Sponsor
- MD Stem Cells
Amyotrophic Lateral Sclerosis (ALS)
Personalized Antisense Oligonucleotide Therapy for Participants With TARDBP ALS
This research project entails delivery of a personalized antisense oligonucleotide (ASO) drug designed for participants with amyotrophic lateral sclerosis (ALS) due to a pathogenic variant in TARDBP.
- Trial name
- NCT07743268
- Testing
- nL-TARDB-006
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- n-Lorem Foundation
Amyotrophic Lateral Sclerosis (ALS)
Safety and Tolerability of Anakinra in Combination With Riluzol in Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis (ALS) is an adult neurodegenerative disease that is caused by a selective degeneration of the motor nerve cells in the cortex and myelon.
- Trial name
- NCT01277315
- Testing
- Anakinra
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Charite University, Berlin, Germany
Amyotrophic Lateral Sclerosis (ALS)
PET Imaging in ALS Patients
This is a pilot study to evaluate a potential imaging biomarker for aiding diagnosis and monitoring progression of ALS, based on a well established basic science pathway, published human autopsy data, preliminary data in ALS…
- Trial name
- NCT02236897
- Testing
- PET Scanning
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
ALS - Amyotrophic Lateral Sclerosis
Atalante Exoskeleton in the Rehabilitation of Patients With Amyotrophic Lateral Sclerosis
Using a MRI gait motor imagery paradigm in ALS patients in order to study how ALS affects the function of the central neural networks involved in gait function, we showed a reorganization of the motor networks that represents a…
- Trial name
- EXALS (NCT06199284)
- Testing
- Atalante exoskeleton
- Where
- 3 sites in France
- Volunteers
- 20 people
- Sponsor
- Institut de Recherche sur la Moelle épinière et l'Encéphale
Amyotrophic Lateral Sclerosis
Multiple Doses of AT-1501-A201 in Adults With ALS
This is a Phase 2a, multi-center, open label, multiple dose study of AT-1501, a humanized monoclonal antibody antagonist to CD40 ligand (CD40L).
- Trial name
- NCT04322149
- Testing
- AT-1501
- Where
- 13 sites in United States, Canada
- Volunteers
- 54 people
- Sponsor
- Anelixis Therapeutics, LLC
Amyotrophic Lateral Sclerosis, Alzheimer Disease
Study of the Role of G72 in Amyotrophic Lateral Sclerosis: Biomarker Discovery and Mechanism Investigation
G72 gene is located on the common linkage locus in bipolar disorder and schizophrenia, and it encodes D-amino acid oxidase activator (DAOA).
- Conditions
- Amyotrophic Lateral Sclerosis, Alzheimer Disease, Parkinson's Disease
- Trial name
- NCT01378026
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- China Medical University Hospital
Motor Neuron Disease, Amyotrophic Lateral Sclerosis
Validation Of Tidal/End -Tidal CO2 in ALS
The study team propose that a new, hand-held test device may be valuable in the management of breathing failure in patients with Motor Neurone Disease (MND).
- Trial name
- VOTECO2ALS (NCT03764384)
- Where
- United Kingdom
- Volunteers
- 200 people
- Sponsor
- Papworth Hospital NHS Foundation Trust